Technical Data
| Formula | C26H24F4N6O |
|||
| Molecular Weight | 512.5 | CAS No. | 1258861-20-9 | |
| Solubility (25°C)* | In vitro | DMSO | 0.66 mg/mL (1.28 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signalling in Phase 1/2. | |
|---|---|---|
| Targets |
|
|
| In vitro | Taladegib (LY2940680) inhibits cancer growth in cell lines containing a mutation in the gene encoding Smoothened that researchers had previously observed in patients with cancer who developed resistance to vismodegib. | |
| In Vivo | Taladegib (LY2940680) has excellent pharmacokinetic properties in rodent and non-rodent species. When administered orally to Ptch+/- p53-/- transgenic mice which spontaneously develop medulloblastoma, it produces remarkable efficacy and significantly improves their survival. This compound reveals rapid kinetics of anti-tumour activity through magnetic resonance imaging of these mice, and induces Caspase-3 activity and reduces proliferation by immunohistochemistry analysis of medulloblastoma tumours. It inhibits Hh regulated gene expression in the subcutaneous xenograft tumour stroma and produces significant anti-tumour activity. |
Protocol (from reference)
References
|
Sellecks Taladegib (LY2940680) Has Been Cited by 5 Publications
| Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] | PubMed: 34997030 |
| A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application [ Carcinogenesis, 2020, 41(7):993-1004] | PubMed: 31740922 |
| L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo. [ Front Pharmacol, 2019, 10:89] | PubMed: 30846937 |
| DRUGPATH - a novel bioinformatic approach identifies DNA-damage pathway as a regulator of size maintenance in human ESCs and iPSCs [ Sci Rep, 2019, 9(1):1897] | PubMed: 30760778 |
| MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. [Hoch L, et al. FASEB J, 2015, 29(5):1817-29] | PubMed: 25636740 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.